AdAlta Limited (AS X:1AD) | Investor Presentation | August 2026 | 1 COMMERCIALISING LIFE SAVING CELLULAR IMMUNOTHERAPIES “EAST TO WEST” ADALTA LIMITED (ASX:1AD) | INVESTOR PRESENTATION | AUGUST 2026 AdAlta Limited (AS X:1AD) | Investor...
Investor presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from AdAlta
- EW-001 IIT study overall survival update
- 2 year survival milestone for EW-001 patient
- Quarterly Appendix 4C and Activities Report
- Oktopi AI collaboration for research efficiency
- Second BZDS1901 milestone paid
Later from AdAlta
- Preliminary Final Report
- Annual Report to shareholders
- Appendix 4G and Corporate Governance Statement
- BZDS1901 special access scheme launch in China
- Bilingual BIOSeedin Investor Presentation
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta